Bryan, Garnier & Co upgraded shares of Travere Therapeutics (NASDAQ:TVTX – Get Rating) from a sell rating to a neutral rating in a research report released on Friday, Briefing.com reports. Several other research firms have also issued reports on TVTX. Piper Sandler lowered their target price on shares of Travere Therapeutics from $44.00 to $41.00 […]
Bryan, Garnier & Co upgraded shares of Travere Therapeutics (NASDAQ:TVTX – Get Rating) from a sell rating to a neutral rating in a report released on Friday, Briefing.com reports. A number of other brokerages have also weighed in on TVTX. Evercore ISI reduced their price objective on shares of Travere Therapeutics from $36.00 to $26.00 […]
Bryan, Garnier & Co started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) in a research report report published on Friday morning, Briefing.com reports. The firm issued a buy rating and a $3.60 price target on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Guggenheim upgraded shares […]